Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension study of orally administered PHA-022121 for acute treatment of hereditary angioedema attacks
2021-006906-58Phase 2Active
- Sponsor
- Pharvaris
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of deucrictibant in hereditary angioedema type I (HAE-I) and Hereditary Angioedema Type 2 (HAE2), sponsored by Pharvaris. Primary endpoints: Safety of long-term on-demand treatment with PHA-022121 and Efficacy in achieving symptom relief. Started May 2022; status: active.
02
Drugs
deucrictibant
03
Conditions
hereditary angioedema type I (HAE-I)Hereditary Angioedema Type 2 (HAE2)
Beyond the preview
Go deeper on 2021-006906-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006906-58.